scholarly article | Q13442814 |
P50 | author | Geoffrey R Hill | Q38327210 |
Andrew D. Clouston | Q38548319 | ||
Andrew W. Roberts | Q43445505 | ||
Kate A Markey | Q46223789 | ||
Kelli P MacDonald | Q55686060 | ||
Yana A Wilson | Q60644270 | ||
P2093 | author name string | Warren S Alexander | |
Joel Tocker | |||
Rachel D Kuns | |||
Alistair L J Don | |||
Neil C Raffelt | |||
Stuart D Olver | |||
P2860 | cites work | A family of cytokine-inducible inhibitors of signalling | Q24313168 |
Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells | Q24547568 | ||
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation | Q24654107 | ||
Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain | Q28140535 | ||
SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor β2 subunit | Q28209831 | ||
Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities | Q28584827 | ||
STATs in cancer inflammation and immunity: a leading role for STAT3 | Q29547203 | ||
The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes | Q33470222 | ||
NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. | Q34078681 | ||
SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis | Q34619592 | ||
CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. | Q35006074 | ||
Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease | Q36141721 | ||
High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. | Q36367196 | ||
Advances in the understanding of acute graft-versus-host disease. | Q36759581 | ||
Prevention of graft versus host disease by inactivation of host antigen-presenting cells | Q78016071 | ||
Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis | Q80353010 | ||
Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells | Q81377803 | ||
Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-gamma receptor-deficient hosts | Q81451703 | ||
Suppressor of cytokine Signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex | Q82858440 | ||
SOCS proteins, cytokine signalling and immune regulation | Q36831668 | ||
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease | Q36843812 | ||
STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. | Q37003577 | ||
IL-17 contributes to CD4-mediated graft-versus-host disease | Q37071147 | ||
Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa | Q37157967 | ||
Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease | Q37373067 | ||
Regulation of immune responses by interleukin-27. | Q37374967 | ||
Memory T cells in GVHD and GVL. | Q37471741 | ||
SOCS3 negatively regulates IL-6 signaling in vivo | Q38354512 | ||
Soluble lymphotoxin is an important effector molecule in GVHD and GVL. | Q39793545 | ||
TGF-beta promotes Th17 cell development through inhibition of SOCS3. | Q39950912 | ||
Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction | Q40716523 | ||
Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance | Q40743352 | ||
Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1 | Q42766950 | ||
Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation | Q46140762 | ||
IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages | Q46376203 | ||
Adaptive immunity maintains occult cancer in an equilibrium state | Q46891052 | ||
Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. | Q47262629 | ||
CD40-CD154 interaction and IFN-gamma are required for IL-12 but not prostaglandin E2 secretion by microglia during antigen presentation to Th1 cells. | Q48286228 | ||
Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. | Q50776421 | ||
SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. | Q51027830 | ||
Helminth-modified pulmonary immune response protects mice from allergen-induced airway hyperresponsiveness. | Q51827445 | ||
Suppressor of cytokine signaling 3 regulates CD8 T-cell proliferation by inhibition of interleukins 6 and 27. | Q53543101 | ||
Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function | Q56901192 | ||
Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma | Q57252626 | ||
IFN differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract | Q57252630 | ||
TGF- in allogeneic stem cell transplantation: friend or foe? | Q57252637 | ||
Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation | Q57252638 | ||
Mechanism of crosstalk inhibition of IL-6 signaling in response to LPS and TNFα | Q62818261 | ||
An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin | Q71881409 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 287-296 | |
P577 | publication date | 2010-04-30 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | SOCS3 regulates graft-versus-host disease | |
P478 | volume | 116 |
Q56888756 | A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab |
Q45050218 | Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. |
Q38661579 | Cellular and molecular mechanisms in graft-versus-host disease |
Q37603497 | Combined nifuroxazide and SAT05f therapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation |
Q27334479 | Critical and independent role for SOCS3 in either myeloid or T cells in resistance to Mycobacterium tuberculosis |
Q92446001 | Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy |
Q88573546 | Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis |
Q39200920 | Epigenetic factors as drivers of fibrosis in systemic sclerosis |
Q36761824 | Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation |
Q37683419 | Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. |
Q45278539 | Microsatellite scanning of the immunogenome associates MAPK14 and ELTD1 with graft-versus-host disease in hematopoietic stem cell transplantation |
Q90360119 | SMG1 heterozygosity exacerbates haematopoietic cancer development in Atm null mice by increasing persistent DNA damage and oxidative stress |
Q35226610 | SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation |
Q37592325 | SOCS3, a Major Regulator of Infection and Inflammation. |
Q36568009 | Smg1 haploinsufficiency predisposes to tumor formation and inflammation |
Q92525927 | Suppressor of cytokine signaling genes in renal transplant receivers: Association with transplant fate |
Q37973866 | The IL-17 differentiation pathway and its role in transplant outcome |
Q37989141 | The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics. |
Q49222418 | Therapeutic effects of STAT3 inhibition by nifuroxazide on murine acute graft graft-vs.-host disease: Old drug, new use. |
Search more.